49 results
Page 2 of 3
6-K
EX-4.3
2pwo3
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
g6g1h 4ru894
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
u33gws5l
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
F-3
EX-4.2
usfoet z6o
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
eztwzbj6w7vzvc
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.1
u1a8cvdyg32qq7 mgn
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
y8kl keoyccd8
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
jngmdj5h5xcbw85 3h
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-3.1
vi5amp3js9
20 May 19
Current report (foreign)
5:28pm
6-K
a2dzm
28 Sep 18
Current report (foreign)
8:40am
424B5
dio0y61g0eq htqz60
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
eyg2 q7phd8ctuz
18 Jun 18
Prospectus supplement for primary offering
9:15pm
6-K
EX-99.1
46t o8zxmj
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
igovdii57n
7 Jun 17
Current report (foreign)
12:00am
20-F
ke3l05sch
21 Apr 17
Annual report (foreign)
12:00am
F-1
a9d8kihu785 pc6o
30 Dec 16
Registration statement (foreign)
12:00am